LSD Analogues for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

LSD Analogues for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

LSD analogues split into two groups: online research chemicals that turn back into LSD, and engineered molecules built to keep brain-connection growth while removing the trip. The most consistent finding is brain-connection growth, hinting at antidepressant and anti-addiction effects, but evidence is mostly from animals. Unregulated versions carry unpredictable dosing, raised blood pressure, and psychiatric risk. (Full Review)

Protocol

Administration
Single supervised oral dose
Under medical monitoring with psychological preparation and integration
Best time of day
Morning
Long duration (effects last 8–12 hours) avoids sleep disruption
Single versus split dosing
Single dose per session
Spaced/cycled; rapid tolerance makes daily use lose effect
Time to effect
Antidepressant benefit
Days to weeks
May build after a session, by analogy to LSD trials
Acute onset
30–90 minutes
For analogues that convert to or mimic LSD
Acute duration
8–12 hours
Engineered analogue time-to-benefit in humans unknown

Benefits

Contraindications
  • Personal or family history of schizophrenia or other psychotic disorders
  • Bipolar disorder (mania risk)
  • Significant cardiovascular disease, uncontrolled hypertension, or known cardiac valvulopathy
  • Recent myocardial infarction (<90 days)
  • Pregnancy or breastfeeding
  • Severe hepatic impairment (Child-Pugh Class C)
  • Illegal or unapproved in most jurisdictions
    •
Key Interactions
  • Serotonergic antidepressants (SSRIs such as fluoxetine/sertraline, SNRIs such as venlafaxine, MAOIs such as phenelzine)
  • Lithium and tricyclic antidepressants
  • Other serotonergic / 5-HT2A agents and triptans (sumatriptan)
  • Other vasopressors and stimulants (pseudoephedrine, excess caffeine, recreational stimulants)
  • Supplements with serotonergic or blood-pressure effects (5-HTP, St. John's wort, tryptophan, synephrine, high-dose yohimbine)
  • CYP-modulating drugs and foods (CYP3A4 inhibitors such as ketoconazole, ritonavir, and grapefruit juice)
    •

Risk & Side Effects

  • High: Dose and purity uncertainty; acute psychological distress; cardiovascular stimulation
    •
  • Medium: Cardiac valve risk; psychosis and prolonged psychiatric reactions
    •
  • Low: Hallucinogen persisting perception disorder; nausea, headache, dizziness, and fatigue
    •
  • Speculative: Long-term organ or metabolic toxicity from novel analogues; unpredictable drug–drug interactions
    •

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Detects hypertension that the drug can worsen
Heart rate 60–80 bpm resting Tracks cardiovascular stimulation
Depression/anxiety rating (e.g., MADRS/PHQ-9, GAD-7) Score in remission range (e.g., PHQ-9 <5) Defines therapeutic response
Echocardiogram (cardiac valves) No valve thickening/regurgitation Screens for 5-HT2B-related valvulopathy with chronic use
Liver function (ALT/AST) ALT/AST within optimal low-normal range Liver clears prodrug analogues; flags impairment
Comprehensive metabolic panel Within optimal functional ranges General safety screen for organ function

Cadence: Continuous blood-pressure and heart-rate observation during acute exposure; blood pressure and mood scales reassessed each session and roughly every 1–3 months; cardiac valve screening every 6–12 months if chronic exposure occurs.

Qualitative Assessment

  • Sustained improvement in mood, outlook, and motivation
  • Reduced anxiety and rumination
  • Cognitive clarity and absence of lingering perceptual disturbances (no HPPD symptoms)
  • Quality and continuity of sleep after dosing
  • Absence of distressing or destabilizing psychological after-effects
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.